Vanguard Asset Management
PHAT icon

Vanguard Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Vanguard Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Hold
28,506
– – ﹤0.01% 2326
2026
Q1 		$317K Buy
+28,506
New +$360K ﹤0.01% 2282

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Asset Management's PHAT Position: Q2 2026 in Review

Vanguard Asset Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 28,506 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Vanguard Asset Management first reported a position in PHAT in Q1 2026 and has held it in 2 quarters since. The position peaked at $317K in Q1 2026. 146 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Vanguard Asset Management held 28,506 shares of Phathom Pharmaceuticals worth $309K as of Q2 2026.
  • Vanguard Asset Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2326 holding.
  • Vanguard Asset Management first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Phathom Pharmaceuticals position peaked at $317K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.